000771468 000__ 04938cam\a2200529Ii\4500
000771468 001__ 771468
000771468 005__ 20230306142609.0
000771468 006__ m\\\\\o\\d\\\\\\\\
000771468 007__ cr\un\nnnunnun
000771468 008__ 140911t20142015sz\a\\\\ob\\\\000\0\eng\d
000771468 019__ $$a894170308
000771468 020__ $$a9783319107110$$q(electronic book)
000771468 020__ $$a3319107119$$q(electronic book)
000771468 020__ $$z9783319107103
000771468 0247_ $$a10.1007/978-3-319-10711-0$$2doi
000771468 035__ $$aSP(OCoLC)ocn890371346
000771468 035__ $$aSP(OCoLC)890371346$$z(OCoLC)894170308
000771468 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dN$T$$dYDXCP$$dCOO$$dOCLCF$$dEBLCP$$dDEBSZ$$dOCLCO$$dOCLCQ$$dOCLCO$$dOCLCQ$$dIAO$$dIAS$$dIAD$$dJBG
000771468 049__ $$aISEA
000771468 050_4 $$aRS201.N35
000771468 08204 $$a620/.5$$223
000771468 24500 $$aLipid nanoparticles :$$bproduction, characterization and stability /$$cRohan Shah, Daniel Eldridge, Enzo Palombo, Ian Harding.
000771468 264_1 $$aCham :$$bSpringer,$$c[2014]
000771468 264_4 $$c©2015
000771468 300__ $$a1 online resource (ix, 97 pages) :$$billustrations.
000771468 336__ $$atext$$btxt$$2rdacontent
000771468 337__ $$acomputer$$bc$$2rdamedia
000771468 338__ $$aonline resource$$bcr$$2rdacarrier
000771468 4901_ $$aSpringerBriefs in Pharmaceutical Science & Drug Development,$$x1864-8118
000771468 504__ $$aIncludes bibliographical references.
000771468 5050_ $$aPreface; Contents; 1 Introduction; Abstract ; 1.1 The Rationale of Introducing Colloidal Carriers; 1.2 Introduction to Colloidal Drug Carriers; 1.3 Lipid Nanoparticles: History and Scope; 1.4 Lipid Nanoparticles: Types; 1.4.1 Solid Lipid Nanoparticle (SLN); 1.4.2 Nanostructured Lipid Carrier (NLC); 1.4.3 Lipid Drug Conjugate (LDC); 1.4.4 Polymer-Lipid Hybrid Nanoparticle (PLN); References; 2 Composition and Structure; Abstract ; 2.1 Composition of Lipid Nanoparticles; 2.1.1 Lipids; 2.1.2 Surfactants; 2.1.3 Other Agents; 2.2 Structure of Solid Lipid Nanoparticles.
000771468 5058_ $$a2.2.1 Drug-Enriched Shell Model2.2.2 Drug-Enriched Core Model; 2.2.3 Solid Solution Model; 2.3 Structure of Nanostructured Lipid Carriers; 2.3.1 NLC Type I or "Imperfect Crystal" Type; 2.3.2 NLC Type II or "Multiple" Type; 2.3.3 NLC Type III or "Amorphous" Type; 2.4 Conclusions; References; 3 Production Techniques; Abstract ; 3.1 General Considerations; 3.2 Production of Lipid Nanoparticles; 3.2.1 High Pressure Homogenization; 3.2.1.1 Hot Homogenization; 3.2.1.2 Cold Homogenization; 3.2.2 Microemulsion Technique; 3.2.3 Microwave-Assisted Microemulsion Technique; 3.2.4 Solvent Evaporation.
000771468 5058_ $$a3.2.5 Double Emulsion3.2.6 Solvent Diffusion; 3.2.7 Solvent Injection (or Displacement); 3.2.8 High Shear Homogenization andor Ultrasound; 3.2.9 Membrane Contactor Method; 3.2.10 Supercritical Fluid Extraction of Emulsions; 3.2.11 Coacervation Technique; 3.2.12 Phase Inversion Temperature Technique; 3.3 Conclusions; References; 4 Characterization; Abstract ; 4.1 Particle Size; 4.1.1 Photon Correlation Spectroscopy; 4.1.2 Laser Diffraction; 4.1.3 Field-Flow Fractionation; 4.1.4 Other Techniques; 4.2 Particle Morphology and Ultrastructure; 4.2.1 Transmission Electron Microscopy.
000771468 5058_ $$a4.2.2 Scanning Electron Microscopy4.2.3 Atomic Force Microscopy; 4.3 Surface Charge; 4.4 Crystallinity and Polymorphism; 4.4.1 Differential Scanning Calorimetry; 4.4.2 X-ray Diffraction; 4.4.3 Small Angle X-ray Scattering; 4.5 Co-existence of Addition Colloidal Structures and Interaction with Incorporated Drugs; 4.5.1 Nuclear Magnetic Resonance; 4.5.2 Electron Spin Resonance; 4.6 Conclusions; References; 5 Physicochemical Stability; Abstract ; 5.1 General Considerations; 5.2 Stabilization Mechanisms; 5.2.1 Electrostatic Stabilization; 5.2.2 Steric Stabilization; 5.3 Destabilization Mechanisms.
000771468 5058_ $$a5.3.1 Physical Stability5.3.1.1 Dispersion Modifications; 5.3.1.2 Lipid Modifications; 5.3.2 Chemical Stability; 5.3.2.1 Drug Stability; 5.3.2.2 Phospholipid Stability; 5.3.2.3 Lipid Stability; 5.4 Stability Measurements; 5.4.1 Physical Stability; 5.4.1.1 Modification of Size; 5.4.1.2 Modification of Zeta Potential; 5.4.1.3 Modification of Crystallinity and Polymorphism; 5.4.1.4 Optical Analysis by Turbiscan® Lab; 5.4.2 Chemical Stability; 5.5 Optimization of Stability; 5.5.1 Physical Stability; 5.5.1.1 Steric Stabilization; 5.5.1.2 Electrostatic Stabilization.
000771468 506__ $$aAccess limited to authorized users.
000771468 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed September 11, 2014).
000771468 650_0 $$aNanoparticles.
000771468 650_0 $$aLipids.
000771468 650_0 $$aLipids$$xBiotechnology.
000771468 7001_ $$aShah, Rohan,$$eauthor.
000771468 77608 $$iPrint version:$$aShah, Rohan.$$tLipid Nanoparticles : Production, Characterization and Stability.$$dDordrecht : Springer, ©2014$$z9783319107103
000771468 830_0 $$aSpringerBriefs in pharmaceutical science & drug development.
000771468 85280 $$bebk$$hSpringerLink
000771468 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-10711-0$$zOnline Access$$91397441.1
000771468 909CO $$ooai:library.usi.edu:771468$$pGLOBAL_SET
000771468 980__ $$aEBOOK
000771468 980__ $$aBIB
000771468 982__ $$aEbook
000771468 983__ $$aOnline
000771468 994__ $$a92$$bISE